Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week~* Mean hemoglobin level between 9.0 - 11.5 g/dL during the screening period~* Adequate iron substitution~Exclusion Criteria:~* Contraindications for Erythropoiesis Stimulating Agent (ESA) therapy~* History of Pure Red Cell Aplasia (PRCA), or anti-erythropoietin (EPO) antibodies~* Known Human Immunodeficiency Virus (HIV) or Hepatitis B infection~* Hepatitis C infection on an active treatment~* Symptomatic congestive heart failure (New York Heart Association \[NYHA\] class III and IV)~* Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization~* Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization~* History of malignancy of any organ system~* Systemic lupus erythematous~* Immunocompromized patients~Other In-/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HX575 epoetin alfa (Type: EXPERIMENTAL): HX575, recombinant human epoetin alfa
- US-licensed epoetin alfa (Type: ACTIVE_COMPARATOR): US-licensed recombinant human epoetin alfa

Based on this trial design, predict the completion outcome and termination type (if applicable).